A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
| Autor: | Jim Mintz, Theodore Van Putten, Stephen R. Marder |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Psychosis medicine.medical_specialty medicine.medical_treatment Akathisia Drug Administration Schedule Psychoses Substance-Induced Arts and Humanities (miscellaneous) Brief Psychiatric Rating Scale medicine Haloperidol Humans Psychiatry Psychiatric Status Rating Scales Chemotherapy Dose-Response Relationship Drug Dose comparison medicine.disease Hospitalization Psychiatry and Mental health Schizophrenia Anesthesia Clinical Global Impression Schizophrenic Psychology medicine.symptom Psychology medicine.drug |
| Zdroj: | Archives of general psychiatry. 47(8) |
| ISSN: | 0003-990X |
| Popis: | • Eighty newly admitted or readmitted men with DSM-III schizophrenia were assigned to receive 5, 10, or 20 mg/d of haloperidol for 4 weeks. Staff were not "blind" to dose. By Clinical Global Impression Scale ratings, the 20-mg dose appeared to be superior to both the 5- and 10-mg doses for the first 2 weeks of treatment but not thereafter. On the Brief Psychiatric Rating Scale Schizophrenia factor, the 20-mg dose was superior to the 5-mg dose throughout the trial and tended to be marginally superior to the 10-mg dose after the first 2 weeks of treatment. By the second week of treatment, however, the group receiving the 20-mg dose deteriorated significantly with regard to Brief Psychiatric Rating Scale ratings of Withdrawal-Retardation (blunted affect, motor retardation, and emotional withdrawal) as well as akinesia and akathisia ratings. Furthermore, 35% of patients given 20 mg/d of haloperidol insisted on leaving the hospital against medical advice vs only 4% of those given 5 or 10 mg/d of haloperidol. A 20-mg/d dose of haloperidol, therefore, may have substantial "psychotoxic" effects by the second week of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|